© Reuters. Logo of Mylan Laboratories, a company primarily engaged in the commercialization of generic drugs is pictured in Merignac near Bordeaux
2/2
(Reuters) – Drugmaker Mylan NV’s (O:) merger with Pfizer Inc’s (N:) off-patent branded drug unit, Upjohn, would now close in the second half of 2020 due to the delays surrounding coronavirus, the companies said on Thursday.
The deal was previously expected to close in mid-2020. (https://reut.rs/2Jfcelr)
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Be the first to comment